Breaking News

INC Research Adds Clinical Trial Technology

Innovative ECG monitoring and reporting can save time and money in early drug development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

INC Research Holdings Inc. is now certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in Phase I clinical development. INC says the use of iCardiac Early Precision QT may help customers reduce costs, and increase the accuracy, reliability and speed of cardiac safety testing in clinical research. “INC Research continually seeks innovations that enhance the full drug development lifecycle,” said Jamie Macdonald, chief executive officer, I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters